Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca and Merck’s LYNPARZA added to bevacizumab reduced the risk of disease progression or death by 41% in the overall…
Opdivo plus low-dose Yervoy combination demonstrated long-term survival for patients with advanced non-small cell lung cancer across PD-L1 expression levels…
AstraZeneca and Merck’s LYNPARZA Added to Bevacizumab Reduced the Risk of Disease Progression or Death by 41% in the Overall…
Zymerowks’ data for HER2-targeted biospecific antibody ZW25, which will be presented at ESMO, support the Initiation of a Registration-Enabling Phase 2 Trial of the ZW25 in second-line HER2-expressing biliary tract cancers.
AVID200 is a first-in-class, rationally designed inhibitor of TGF-beta 1 & 3, the main oncogenic TGF-beta isoforms AVID200 demonstrated peripheral…
Bristol Myers Squib’s adjuvant treatment with Opdivo (nivolumab) further showed extended recurrence-free survival at three years in resected high-risk melanoma patients, being the longest follow-up of any PD-1 inhibitor in the adjuvant melanoma setting.
MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, Inc., a healthcare company focused on the early detection of cancer, today announced that new data…
Growing Body of Evidence Supporting Use of the Tack Endovascular System® to Improve Balloon Angioplasty Outcomes for Patients Suffering from…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the…
Merck’s biopharmaceutical branch, EMD Serono, and Pfizer will present clinical activity of treatment with Bavencio across multiple tumor types and patient populations at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.